Motley FoolHow CSL shares skyrocketed 39% in August
Investors sent CSL shares rocketing 39% in August. But why? The post How CSL shares skyrocketed 39% in August appeared first on The Motley Fool Australia.
Csl (CSL) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXAppendix 3Y - Alison Watkins AM
director_dealing announcement
Appendix 3Y - Elaine Sorg
director_dealing announcement
Appendix 3Y - Costa Saroukos
director_dealing announcement
Appendix 3Y - Cameron Price
director_dealing announcement
Appendix 3Y - Samantha Lewis
director_dealing announcement
Appendix 3Y - Carolyn Hewson AO
director_dealing announcement
Appendix 3Y - Brian Daniels
director_dealing announcement
Appendix 3Y - Andrew Cuthbertson AO
director_dealing announcement
Appendix 3Y - Brian McNamee AO
director_dealing announcement
Notification regarding unquoted securities - CSL
other announcement
CSL shares rebound 86%: Is the ASX biotech stock a buy, sell or hold for September?
Find out why investors are now rushing to buy CSL shares. The post CSL shares rebound 86%: Is the ASX biotech stock a buy, sell or hold for September? appeared first on The Motley Fool Australia.
KalkineCould CSL (ASX:CSL) Draw More Attention Across Healthcare Stocks?
Highlights CSL guided to a return to underlying profit growth, landing ahead of prevailing market expectations. The local healthcare sector has rebounded firmly from its mid-year trough. Plasma collection efficiency and yield gains remain central to the margin recovery story. CSL (ASX:CSL), the Melbourne-headquartered plasma therapies and vaccines group that ranks among the largest names on the Australian market, has set the tone for a healthcare sector emerging from a punishing stretch. Guid...
_09_01_2026_06_26_01_992010.jpg&w=3840&q=65)
ASX 200 Slides as Oil Surges, CSL (ASX:CSL) Defies the Gloom
Highlights Australian shares opened lower as renewed Middle East tensions pushed oil prices higher and weighed on global market sentiment. CSL advanced after agreeing to a US drug-pricing arrangement and reaffirming its commitment to expanding its plasma manufacturing footprint. Financial, retail and technology stocks weakened, while energy and healthcare shares provided support to the local market. The Australian share market began September on a cautious footing, with the ASX 200 movin...
CSL (ASX:CSL) Under Pressure as Oil Surge Sends ASX Lower
Highlights Australian shares came under pressure as surging crude prices and higher bond yields weighed on market sentiment. CSL agreed to lower prices for selected US medicines amid changes in the American healthcare market. AI and technology remained in focus as Gridsight attracted fresh funding while software stocks staged a notable rebound. The Australian share market began September on a cautious footing, with rising oil prices and climbing government bond yields adding pressure acr...
Why Is CSL (ASX:CSL) in Focus as Its Chart tests the annual result surge?
Highlights CSL's updated filing sets operating operation and business rigour at the centre of the current ASX discussion. Demand character, cash delivery and cost settings provide the clearest background for interpreting the update across healthcare shares. Structured market disclosures remain the appropriate evidence reference for considering how the documented priorities are turning into documented activity. Ahead of the freshest ASX session, CSL (ASX:CSL) remains in priority after moving s...
Bond yields climb; CSL to lower prices in Trump deal; AI was meant to kill software, so what happened?
Read everything that’s happened in the news so far today.
CSL signs deal with Trump administration to slash prices for its medicines
Australia’s largest pharma company has agreed to lower the cost of its medicines in the US as it seeks to avoid the 100 per cent tariffs slapped on Australian-made pharmaceuticals.
CSL shares are up more than 40% in a month. What just happened in the US?
The stock’s huge rebound is getting another boost. The post CSL shares are up more than 40% in a month. What just happened in the US? appeared first on The Motley Fool Australia.
Where will CSL shares be in 12 months? Brokers weigh in
Analysts remain divided over CSL’s recovery prospects. The post Where will CSL shares be in 12 months? Brokers weigh in appeared first on The Motley Fool Australia.
Google NewsWhere will CSL shares be in 12 months? Brokers weigh in - The Motley Fool Australia
Where will CSL shares be in 12 months? Brokers weigh in The Motley Fool Australia
Agreements with U.S. on Drug Prices and Manufacturing
other announcement
What Is Driving CSL (ASX:CSL) in Healthcare Stocks?
Highlights The blood products and vaccines group delivered an annual result that sparked one of the sharpest single session moves of reporting season. Plasma collection economics and immunoglobulin demand did most of the work behind the improvement in earnings. Healthcare has swung from persistent laggard to one of the strongest corners of the local market this month. Australian market attention has shifted toward CSL (ASX:CSL) as company-specific developments add a fresh layer to the healthc...
Could CSL (ASX:CSL) FY26 Reset Its Growth Outlook?
Highlights CSLs FY26 result points to a business trying to restore steadier growth after a difficult period marked by repeated expectation resets. CSL Behring remains the central operating engine, while Seqirus and Vifor continue to face more uneven market conditions. The FY27 setup centres on simplification, commercial execution, portfolio discipline and whether recent operating changes can translate into more dependable momentum. Australian healthcare attention has returned to CSL Limited (...
Up 88%! Why CSL shares remain an 'appealing’ buy today - The Motley Fool Australia
Up 88%! Why CSL shares remain an 'appealing’ buy today The Motley Fool Australia
CSL (ASX:CSL) Outlook: Can Margin Recovery Unlock Its Next Phase of Growth? - Kalkine
CSL (ASX:CSL) Outlook: Can Margin Recovery Unlock Its Next Phase of Growth? Kalkine
CSL (ASX:CSL) FY26 Results Highlight Business Reset, Efficiency Improvements and Future Growth Opportunities - Kalkine
CSL (ASX:CSL) FY26 Results Highlight Business Reset, Efficiency Improvements and Future Growth Opportunities Kalkine
CSL shares have surged 49%: Are brokers finally turning bullish?
CSL’s recovery is gathering pace, but has the share price already priced in the turnaround? The post CSL shares have surged 49%: Are brokers finally turning bullish? appeared first on The Motley Fool Australia.
Why Is CSL (ASX:CSL) Facing a Fresh Bluechip Test?
Highlights CSL is drawing attention as bluechip resilience through operational change becomes more important to the Australian market conversation. The companys position across plasma therapies, vaccines and specialist medicines delivered through a global network gives readers a practical lens on changing conditions in global biotechnology. Operational delivery, capital discipline and clear strategic priorities remain central as the sector continues evolving. Australias sharemarket is enterin...
Should I buy CSL shares before the end of August?
I think the company's earnings outlook is starting to look more encouraging. The post Should I buy CSL shares before the end of August? appeared first on The Motley Fool Australia.
Can CSL (ASX:CSL) Rebound After Growth Reset?
Highlights CSL rebounded sharply as management described the past year as a deliberate reset ahead of renewed profit growth. A substantial round of impairments weighed on the statutory outcome even as underlying cash generation remained solid. Cost-saving initiatives flagged for the coming years are expected to underpin a return to steadier earnings growth. CSL (ASX:CSL) [ASX 20] shares rebounded sharply this week after the biotechnology group described its latest annual result as a deliberat...
CSL Shares Shift Positive YTD, As Resistance Turns To Support - thebull.com.au
CSL Shares Shift Positive YTD, As Resistance Turns To Support thebull.com.au
_08_26_2026_08_11_23_188934.jpg&w=3840&q=65)
All Ordinaries: Why Is CSL (ASX:CSL) Back in Focus?
Highlights CSL is being read through support and resistance rather than short-term market movement. The wider technical analysis backdrop is shaped by volume confirmation and relative strength. Operating consistency remains the clearest way to separate company delivery from broad category momentum. Against a [All Ordinaries] benchmark setting, A company-specific reading of CSL begins with price structure and trading participation, especially while the wider market-price behaviour backdrop rem...
Can CSL (ASX:CSL) Turn Its Outlook Into Fresh Momentum?
Highlights A reset year brought large impairments, restructuring charges and a statutory loss The share price reaction tracked guidance for the year ahead rather than the period reported Plasma collection economics and immunoglobulin demand remain the levers under any recovery CSL, Australia's largest healthcare company, reported a full-year result earlier this month that carried heavy one-off charges and a statutory loss, yet the share price answered with one of its sharpest single-session a...
CSL Ltd (ASX:CSL) Stock in Focus: What Investors Need to Know - Kalkine
CSL Ltd (ASX:CSL) Stock in Focus: What Investors Need to Know Kalkine
CSL (ASX:CSL) Turns a Painful Reset Into a Potential Growth Recovery Story - Kalkine
CSL (ASX:CSL) Turns a Painful Reset Into a Potential Growth Recovery Story Kalkine
Buy, hold, sell: CSL, BHP, Westpac shares
Let's start the new week with some fresh ratings from the experts. The post Buy, hold, sell: CSL, BHP, Westpac shares appeared first on The Motley Fool Australia.
CSL and A2 Milk Lead 8 Australian Stocks in Reporting Season Focus
Highlights Strong reporting season updates have placed CSL, A2 Milk and several major Australian companies back in the market spotlight. Healthcare, consumer, mining, financial and technology sectors are driving fresh attention across the Australian market. Company earnings, outlook updates and sector trends are influencing broader market sentiment. Australia's reporting season is once again shaping market direction, with several leading companies attracting renewed attention as fresh fi...
CSL (ASX:CSL) Headline Loss Masks a Bigger Story for Healthcare Giant
Highlights CSL reported a statutory net loss despite broadly steady annual revenue. Management expects underlying earnings to strengthen in the coming financial year. The latest dividend declaration reflects confidence in ongoing cash generation. Australia's share market continues to reward companies that can demonstrate resilience beyond headline numbers, and healthcare giant CSL (ASX:CSL) has become the latest example. As one of the leading names in the Australian healthcare sector and...
Could CSL (ASX:CSL) Strengthen Its Healthcare Stock Appeal?
Highlights CSL is being assessed through demand durability, product adoption and the quality of execution rather than short-term market direction. The healthcare stocks backdrop makes margin quality and research investment especially useful when separating company evidence from sector noise. Upcoming disclosures can clarify whether global execution is supporting or constraining the operating story around CSL. Australian equities are being forced to separate durable operating evidence from sho...
CSL (ASX:CSL) Is Up 24.5% After Posting a Net Loss but Guiding for NPAT Growth - What's Changed - simplywall.st
CSL (ASX:CSL) Is Up 24.5% After Posting a Net Loss but Guiding for NPAT Growth - What's Changed simplywall.st
ASX 200: Why is CSL (ASX:CSL) in focus?
Highlights The distinguishing feature in CSL is the sequencing of research intensity and operating leverage, which makes a generic healthcare stocks reading insufficient. CSL is read through procedure volumes first, with research intensity acting as the next confirmation point. The coverage separates company execution from the wider ASX 200 backdrop instead of treating the market move as the conclusion. Operating leverage provides the counter-check that keeps the analysis tied to the company ra...
_08_20_2026_04_45_08_040027.jpg&w=3840&q=65)
Why Is CSL (ASX:CSL) in Focus on Reversal?
Highlights CSL shares staged a sharp rebound after underlying profit outpaced expectations, snapping a prolonged run of underperformance versus the broader healthcare sector. The chart shows the stock reclaiming ground above a short-term moving average, an early signal chart-watchers associate with a shift in trend. Momentum indicators have swung firmly higher from deeply oversold territory, though the stock remains well below its long-term trend line. CSL Limited (ASX:CSL) shares surged afte...
CSL (ASX:CSL): Why does All Ordinaries context matter?
Highlights Rather than begin with the market narrative, this section starts inside CSL: earnings quality is tested against pricing power before the All Ordinaries context is considered. CSL is approached from the quality of earnings quality, not from a broad market-direction call. The analysis works backwards from operating resilience to test what pricing power is actually saying about the business. That company-first framing keeps the All Ordinaries reference useful without allowing the index ...
Why I'd buy CSL, Cochlear, and Pro Medicus shares
These are three ASX healthcare shares I would be happy to own for years. The post Why I'd buy CSL, Cochlear, and Pro Medicus shares appeared first on The Motley Fool Australia.
Could CSL (ASX:CSL) Rebuild Momentum After Its Latest Earnings Reset?
Highlights CSL has reported a difficult annual result, with statutory earnings pressured despite broadly resilient underlying revenue. Fresh guidance has shifted attention towards whether the healthcare group can restore earnings quality across its core businesses. The companys global plasma, vaccines and specialty therapies portfolio remains central to the recovery narrative. Recent market strength suggests expectations have improved, but execution across margins, product development and debt m...
Can CSL, BHP, WDS and STO Lead the Next ASX Blue-Chip Move?
Highlights Healthcare, energy and mining are presenting very different market signals as commodity prices, earnings expectations and global risk sentiment shift. CSL and Cochlear remain major healthcare names, while BHP, Woodside and Santos bring exposure to resources and energy. Copper, lithium and base metals are also drawing attention as traders reassess sector trends across the Australian market. Australias largest listed companies are moving through a market shaped by changing energy pric...
CSL shares are flying higher. Is it too late to buy?
CSL must now deliver faster earnings growth to justify its rally. The post CSL shares are flying higher. Is it too late to buy? appeared first on The Motley Fool Australia.
CSL Shares: Most Overbought on ASX 200, As Momentum Shifts - thebull.com.au
CSL Shares: Most Overbought on ASX 200, As Momentum Shifts thebull.com.au
How much are CSL shares worth? 4 brokers have their say
There are a wide range of views on this stock. The post How much are CSL shares worth? 4 brokers have their say appeared first on The Motley Fool Australia.
CSL (ASX:CSL) Reported A Net Loss, Is The Rebound Already Priced In? - simplywall.st
CSL (ASX:CSL) Reported A Net Loss, Is The Rebound Already Priced In? simplywall.st